Your browser doesn't support javascript.
loading
Broad sarbecovirus neutralization by a human monoclonal antibody.
Tortorici, M Alejandra; Czudnochowski, Nadine; Starr, Tyler N; Marzi, Roberta; Walls, Alexandra C; Zatta, Fabrizia; Bowen, John E; Jaconi, Stefano; Di Iulio, Julia; Wang, Zhaoqian; De Marco, Anna; Zepeda, Samantha K; Pinto, Dora; Liu, Zhuoming; Beltramello, Martina; Bartha, Istvan; Housley, Michael P; Lempp, Florian A; Rosen, Laura E; Dellota, Exequiel; Kaiser, Hannah; Montiel-Ruiz, Martin; Zhou, Jiayi; Addetia, Amin; Guarino, Barbara; Culap, Katja; Sprugasci, Nicole; Saliba, Christian; Vetti, Eneida; Giacchetto-Sasselli, Isabella; Fregni, Chiara Silacci; Abdelnabi, Rana; Foo, Shi-Yan Caroline; Havenar-Daughton, Colin; Schmid, Michael A; Benigni, Fabio; Cameroni, Elisabetta; Neyts, Johan; Telenti, Amalio; Virgin, Herbert W; Whelan, Sean P J; Snell, Gyorgy; Bloom, Jesse D; Corti, Davide; Veesler, David; Pizzuto, Matteo Samuele.
Afiliación
  • Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Czudnochowski N; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
  • Starr TN; Vir Biotechnology, San Francisco, CA, USA.
  • Marzi R; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Walls AC; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Zatta F; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Bowen JE; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Jaconi S; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Di Iulio J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Wang Z; Vir Biotechnology, San Francisco, CA, USA.
  • De Marco A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Zepeda SK; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Pinto D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Liu Z; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Beltramello M; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Bartha I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Housley MP; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
  • Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
  • Dellota E; Vir Biotechnology, San Francisco, CA, USA.
  • Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
  • Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
  • Zhou J; Vir Biotechnology, San Francisco, CA, USA.
  • Addetia A; Vir Biotechnology, San Francisco, CA, USA.
  • Guarino B; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Culap K; Vir Biotechnology, San Francisco, CA, USA.
  • Sprugasci N; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Saliba C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Vetti E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Giacchetto-Sasselli I; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Abdelnabi R; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Foo SC; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Havenar-Daughton C; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Schmid MA; Vir Biotechnology, San Francisco, CA, USA.
  • Benigni F; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Neyts J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Telenti A; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Virgin HW; Vir Biotechnology, San Francisco, CA, USA.
  • Whelan SPJ; Vir Biotechnology, San Francisco, CA, USA.
  • Snell G; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Bloom JD; Vir Biotechnology, San Francisco, CA, USA.
  • Corti D; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Veesler D; Howard Hughes Medical Institute, Seattle, WA, USA.
  • Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.
Nature ; 597(7874): 103-108, 2021 09.
Article en En | MEDLINE | ID: mdl-34280951
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos ampliamente neutralizantes / SARS-CoV-2 / COVID-19 / Anticuerpos Monoclonales / Anticuerpos Antivirales Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos ampliamente neutralizantes / SARS-CoV-2 / COVID-19 / Anticuerpos Monoclonales / Anticuerpos Antivirales Idioma: En Revista: Nature Año: 2021 Tipo del documento: Article